[1]
NOWELL PC, HUNGERFORD DA. Chromosome studies on normal and leukemic human leukocytes. Journal of the National Cancer Institute. 1960 Jul:25():85-109
[PubMed PMID: 14427847]
[2]
Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. International journal of hematology. 2001 Apr:73(3):278-91
[PubMed PMID: 11345193]
[3]
Rowley JD. Genetics. A story of swapped ends. Science (New York, N.Y.). 2013 Jun 21:340(6139):1412-3. doi: 10.1126/science.1241318. Epub
[PubMed PMID: 23788787]
[4]
Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, Liu Q. The Philadelphia chromosome in leukemogenesis. Chinese journal of cancer. 2016 May 27:35():48. doi: 10.1186/s40880-016-0108-0. Epub 2016 May 27
[PubMed PMID: 27233483]
[5]
Zhang LJ, Gan YM, Yu L. Occurrence of BCR/ABL fusion gene in a patient with acute promyelocytic leukemia. Medical oncology (Northwood, London, England). 2015 Jan:32(1):382. doi: 10.1007/s12032-014-0382-0. Epub 2014 Nov 27
[PubMed PMID: 25428388]
[6]
Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature. 1987 Feb 12-18:325(6105):631-5
[PubMed PMID: 3543692]
[7]
Verrma SP, Dutta TK, Vinod KV, Dubashi B, Ariga KK. Philadelphia chromosome positive pre-T cell acute lymphoblastic leukemia: a rare case report and short review. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion. 2014 Sep:30(Suppl 1):177-9. doi: 10.1007/s12288-013-0314-8. Epub 2014 Jan 22
[PubMed PMID: 25332571]
Level 3 (low-level) evidence
[8]
Advani AS, Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leukemia research. 2002 Aug:26(8):713-20
[PubMed PMID: 12191565]
[9]
Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 1996 Oct 1:88(7):2410-4
[PubMed PMID: 8839830]
[10]
Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011 Mar 17:117(11):3163-71. doi: 10.1182/blood-2010-10-314682. Epub 2011 Jan 12
[PubMed PMID: 21228332]
[11]
Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (New York, N.Y.). 1986 Jul 11:233(4760):212-4
[PubMed PMID: 3460176]
[12]
Koretzky GA. The legacy of the Philadelphia chromosome. The Journal of clinical investigation. 2007 Aug:117(8):2030-2
[PubMed PMID: 17671635]
[13]
Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer research. 2007 Jul 15:67(14):7045-53
[PubMed PMID: 17638918]
[14]
Tao WJ, Lin H, Sun T, Samanta AK, Arlinghaus R. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor. Oncogene. 2008 May 15:27(22):3194-200
[PubMed PMID: 18071309]
[15]
Warsch W, Walz C, Sexl V. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood. 2013 Sep 26:122(13):2167-75. doi: 10.1182/blood-2013-02-485573. Epub 2013 Aug 7
[PubMed PMID: 23926299]
[16]
Valent P. Targeting the JAK2-STAT5 pathway in CML. Blood. 2014 Aug 28:124(9):1386-8. doi: 10.1182/blood-2014-07-585943. Epub
[PubMed PMID: 25170113]
[17]
Li Q, Wu Y, Fang S, Wang L, Qi H, Zhang Y, Zhang J, Li W. BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts. Cancer gene therapy. 2015 May:22(5):227-37. doi: 10.1038/cgt.2014.65. Epub 2015 Apr 3
[PubMed PMID: 25837664]
Level 2 (mid-level) evidence
[18]
Enciso J, Mendoza L, Pelayo R. Normal vs. Malignant hematopoiesis: the complexity of acute leukemia through systems biology. Frontiers in genetics. 2015:6():290. doi: 10.3389/fgene.2015.00290. Epub 2015 Sep 11
[PubMed PMID: 26442108]
[19]
Kuroda I, Inukai T, Zhang X, Kikuchi J, Furukawa Y, Nemoto A, Akahane K, Hirose K, Honna-Oshiro H, Goi K, Kagami K, Yagita H, Tauchi T, Maeda Y, Sugita K. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia. Oncogene. 2013 Mar 28:32(13):1670-81. doi: 10.1038/onc.2012.186. Epub 2012 Jun 4
[PubMed PMID: 22665066]
[20]
Zhao S, Asgary Z, Wang Y, Goodwin R, Andreeff M, Younes A. Functional expression of TRAIL by lymphoid and myeloid tumour cells. British journal of haematology. 1999 Sep:106(3):827-32
[PubMed PMID: 10468881]
[21]
Pereira WO, De Carvalho DD, Zenteno ME, Ribeiro BF, Jacysyn JF, Sardinha LR, Zanichelli MA, Hamerschlak N, Jones GE, Pagnano KB, Castro FA, Calle Y, Amarante-Mendes GP. BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. Cell death & disease. 2017 Oct 12:8(10):e3114. doi: 10.1038/cddis.2017.458. Epub 2017 Oct 12
[PubMed PMID: 29022901]
[22]
Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, Akashi K, Tenen DG. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004 Dec:21(6):853-63
[PubMed PMID: 15589173]
[23]
Ilaria R Jr. Bcr/Abl, leukemogenesis, and genomic instability: a complex partnership. Leukemia research. 2002 Nov:26(11):971-3
[PubMed PMID: 12363461]
[24]
Gerber JM, Gucwa JL, Esopi D, Gurel M, Haffner MC, Vala M, Nelson WG, Jones RJ, Yegnasubramanian S. Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations. Oncotarget. 2013 May:4(5):715-28
[PubMed PMID: 23651669]
[25]
Beer PA, Knapp DJ, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J, Druker BJ, Loriaux MM, Loeb KR, Radich JP, Erber WN, Eaves CJ. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood. 2015 Jan 15:125(3):504-15. doi: 10.1182/blood-2014-06-581173. Epub 2014 Nov 4
[PubMed PMID: 25370416]
[26]
Nacheva EP, Brazma D, Virgili A, Howard-Reeves J, Chanalaris A, Gancheva K, Apostolova M, Valgañon M, Mazzullo H, Grace C. Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC genomics. 2010 Jan 18:11():41. doi: 10.1186/1471-2164-11-41. Epub 2010 Jan 18
[PubMed PMID: 20082691]
[27]
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007 Apr 12:446(7137):758-64
[PubMed PMID: 17344859]
[28]
Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, Gale RE, Linch DC, Hills RK, Russell N, Burnett AK, Kottaridis PD. Does BCR/ABL1 positive acute myeloid leukaemia exist? British journal of haematology. 2013 May:161(4):541-50. doi: 10.1111/bjh.12301. Epub 2013 Mar 25
[PubMed PMID: 23521501]
[29]
Xie J, Wang Q, Wang Q, Yao H, Wen L, Ma L, Wu D, Chen S. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia. Cancer genetics. 2014 May:207(5):226-30. doi: 10.1016/j.cancergen.2014.05.003. Epub 2014 May 16
[PubMed PMID: 24998463]
[31]
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. American journal of hematology. 2018 Mar:93(3):442-459. doi: 10.1002/ajh.25011. Epub
[PubMed PMID: 29411417]
[32]
Khan M, Siddiqi R, Tran TH. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options. Seminars in hematology. 2018 Oct:55(4):235-241. doi: 10.1053/j.seminhematol.2018.05.001. Epub 2018 May 29
[PubMed PMID: 30502852]
Level 2 (mid-level) evidence
[33]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015 Jan-Feb:65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5
[PubMed PMID: 25559415]
[34]
Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007 Feb 1:109(3):926-35
[PubMed PMID: 17003380]
[35]
Pullarkat V, Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008 Mar 1:111(5):2563-72
[PubMed PMID: 18156492]
[36]
Soupir CP, Vergilio JA, Dal Cin P, Muzikansky A, Kantarjian H, Jones D, Hasserjian RP. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. American journal of clinical pathology. 2007 Apr:127(4):642-50
[PubMed PMID: 17369142]
[37]
Shimizu H, Yokohama A, Hatsumi N, Takada S, Handa H, Sakura T, Nojima Y. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. European journal of haematology. 2014 Oct:93(4):297-301. doi: 10.1111/ejh.12343. Epub 2014 May 13
[PubMed PMID: 24750307]
[38]
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov:31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14
[PubMed PMID: 28804124]
Level 1 (high-level) evidence
[39]
Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International journal of hematology. 2014:99(5):616-24
[PubMed PMID: 24658916]
[40]
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jul 10:34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23
[PubMed PMID: 27217448]
[41]
Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. International journal of hematology. 2018 Mar:107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26
[PubMed PMID: 29076005]
Level 1 (high-level) evidence
[42]
Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984 Apr:63(4):789-99
[PubMed PMID: 6584184]
[43]
Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. Journal of the National Cancer Institute. 1998 Jun 3:90(11):850-8
[PubMed PMID: 9625174]
[44]
Müller MC,Cervantes F,Hjorth-Hansen H,Janssen JJWM,Milojkovic D,Rea D,Rosti G, Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Critical reviews in oncology/hematology. 2017 Dec;
[PubMed PMID: 29198338]
Level 3 (low-level) evidence
[45]
Khoury HJ, Cortes J, Baccarani M, Wetzler M, Masszi T, Digumarti R, Craig A, Benichou AC, Akard L. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leukemia & lymphoma. 2015 Jan:56(1):120-7. doi: 10.3109/10428194.2014.889826. Epub 2014 Apr 28
[PubMed PMID: 24650054]
[46]
Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. The American journal of medicine. 1987 Sep:83(3):445-54
[PubMed PMID: 3477958]